Cadrenal Therapeutics Rings the Closing Bell in Celebration of its IPO
About This Event
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, visits the Nasdaq MarketSite in Times Square.
In honor of the occasion, Quang Pham, Chairman and CEO, rings the Closing Bell.